Transition Bio Funding: $50M Raised, Series A (2022)
Transition Bio is based in Cambridge, MA. It has raised $50M in total funding. Latest round: Series A.
Transition Bio funding overview
Transition Bio is based in Cambridge, MA. Transition Bio has raised $50M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in January 2022. The round record for Transition Bio runs through 2022; nothing later has been disclosed. Investors on record include Northpond Ventures, Taiho Ventures, Bristol Myers Squibb, Magnetic Ventures, Lifeforce Capital. 5 distinct backers are named across the disclosed rounds.
Transition Bio at a glance
Total raised
$50M
Latest round
Series A
Latest round date
January 2022
Headquarters
Cambridge, MA
Notable investors
Northpond Ventures, Taiho Ventures, Bristol Myers Squibb, Magnetic Ventures, Lifeforce Capital
Frequently asked about Transition Bio funding
How much has Transition Bio raised?
Transition Bio has raised $50M in total disclosed funding across the rounds on record.
Who has invested in Transition Bio?
Northpond Ventures, Taiho Ventures, Bristol Myers Squibb, Magnetic Ventures, Lifeforce Capital are named among the investors backing Transition Bio.
What was the latest Transition Bio funding round?
The most recent disclosed round is a Series A, announced in January 2022.
Where is Transition Bio based?
Transition Bio is based in Cambridge, MA.
When did Transition Bio last raise?
The last disclosed Transition Bio round closed in January 2022 at Series A.
Totals shown for Transition Bio aggregate every disclosed round on file. To see how that compares, browse the companies in Cambridge and the investors behind them below.
